type 1 diabetes and insulin therapy
Manage T1DM with automated insulin delivery (AID) first-line when willing and able, or basal-bolus insulin analogues + real-time CGM. Never stop basal insulin in T1DM — even when NPO. In hospital, use proactive basal-bolus + correction (not sliding scale alone), targeting 5.0–8.0 mmol/L preprandial and <10.0 mmol/L random on the ward (6.0–10.0 mmol/L in ICU).
T1DM insulin delivery and technology
Diabetes Canada 2025 makes AID (hybrid closed-loop pump + rtCGM) the preferred delivery system for all individuals with T1DM willing to wear it (Grade A, Level 1A — improves A1C, TIR, hypoglycaemia, and diabetes distress without increasing DKA).
| regimen | role | key clinical points |
|---|---|---|
| AID (automated insulin delivery) | first-line for all willing/able | treats non-severe hypoglycaemia with 5–10 g carbs (not 15 g) because the pump has already suspended basal |
| pump (IPT) + PLGS / CGM | second-line if AID unavailable | predictive low-glucose suspend cuts nocturnal and severe hypoglycaemia; counsel on infusion-site rotation and pump failure → rapid DKA |
| basal-bolus injections (BBI) | standard MDI alternative | pair with rtCGM (Grade A) or isCGM; bolus calculators aid dosing |
choosing insulin analogues
- Basal: long-acting analogues (glargine U-100, detemir) over NPH to reduce hypoglycaemia; ultralong-acting analogues (degludec, glargine U-300) further cut nocturnal/severe hypoglycaemia. Prefer daily ultralong-acting over weekly insulin icodec in T1DM (higher hypoglycaemia risk with weekly basal, Grade B).
- Bolus: rapid-acting analogues (aspart, lispro, glulisine) over regular insulin (Grade A); ultrarapid analogues (faster aspart, ultra-rapid lispro) improve postprandial excursions and TIR when not at target. Deliver mealtime boluses 10–20 minutes pre-meal.
- Starting TDD (insulin-naïve T1DM): typically 0.4–0.5 U/kg/day (lower in honeymoon/CKD, higher in puberty/illness), split roughly 50% basal / 50% prandial (adjust ratio 40:60 to 60:40 by pattern).
pattern-based titration and insulin math
Always fix hypoglycaemia first, then fasting glucose (basal), then postprandial excursions (bolus). Look at the dose acting before the abnormal reading:
| glucose pattern | culprit dose | adjustment |
|---|---|---|
| high fasting (pre-breakfast) | bedtime/basal insulin | check 03:00 BG to exclude nocturnal hypo → ↑ basal by 10–20% (wait 2–3 days between degludec changes) |
| high pre-lunch | breakfast bolus | ↑ breakfast bolus (or strengthen breakfast carb ratio) |
| high pre-dinner | lunch bolus | ↑ lunch bolus |
| high bedtime | dinner bolus | ↑ dinner bolus |
| nocturnal hypoglycaemia | excess basal or late dinner/correction stacking | ↓ basal; switch to degludec/glargine U-300; review dinner bolus and evening alcohol/exercise |
- Insulin sensitivity (correction) factor:
100 / TDD(mmol/L drop per 1 U rapid insulin). - Carbohydrate-to-insulin ratio:
500 / TDD(grams of carbohydrate covered by 1 U rapid insulin).
adjunctive non-insulin therapies in T1DM
- Diabetes Canada 2025 gives a conditional recommendation (shared decision-making, off-label) for adult T1DM patients who have specific metabolic goals beyond insulin alone:
- Metformin: modest ↓ A1C, weight, and insulin dose (Grade A).
- GLP-1 RA: ↓ A1C, weight, and insulin dose, but GI side effects and delayed gastric emptying (avoid in gastroparesis).
- SGLT2i: ↓ A1C, glucose variability, and weight, but markedly increases euglycaemic DKA (up to one-third present with BG <13.9 mmol/L) and genital infections. Only consider if willing to monitor blood ketones (STOP DKA protocol) and avoid very-low-carbohydrate diets.
- ADA 2026 does not recommend routine SGLT2i or GLP-1 RA in T1DM due to DKA and lack of outcome data — insulin remains the core therapy, and SGLT2i is never a first-line choice in T1DM.
autoimmune screening and sick-day rules
- Autoimmune comorbidities : screen TSH (± anti-TPO) at diagnosis and periodically (hypothyroidism); screen for coeliac disease (tTG-IgA + total IgA) if GI symptoms, iron/vitamin D deficiency, unexplained hypoglycaemia, or osteoporosis; evaluate for adrenal insufficiency if unexplained recurrent hypoglycaemia, falling insulin requirements, or hyperpigmentation.
- Ketone testing: check capillary β-hydroxybutyrate during acute illness, when preprandial BG stays >14.0 mmol/L, or with nausea/vomiting/abdominal pain (blood BHB detects ketosis earlier than urine strips; BHB >1.5 mmol/L warrants DKA evaluation → diabetic ketoacidosis — management).
inpatient insulin and steroid-induced hyperglycaemia
Measure A1C on admission if none in the past 3 months (for known diabetes or new inpatient hyperglycaemia >7.8 mmol/L; if A1C 6.0–6.4%, re-screen 6–8 weeks post-discharge).
| setting | glycaemic target (DC 2018) | preferred regimen |
|---|---|---|
| non-critically ill ward | preprandial 5.0–8.0, random <10.0 mmol/L | proactive basal + bolus + correction (Grade A over sliding scale alone) |
| critically ill (ICU) | 6.0–10.0 mmol/L (SCCM/SSC 2026: 7.8–11.1 — see icu supportive care) | continuous IV insulin infusion (tighter 4.5–6.0 increases mortality) |
| CABG (intraoperative) | 5.5–11.1 mmol/L | continuous IV insulin infusion (Grade A) |
Even when NPO or acutely ill, patients with T1DM require continuous basal insulin (typically 80–100% of usual basal dose) plus q4–6h correction and dextrose-containing IV fluids if needed — stopping basal precipitates DKA within hours.
- Starting inpatient basal-bolus (insulin-naïve): 0.4–0.5 U/kg/day (lower to 0.2–0.3 U/kg/day in elderly, frail, or CKD), split 40–50% basal + 50–60% divided across 3 meals, plus correction scale. If NPO, give basal + q4–6h rapid correction (check CBG q4–6h; q1–2h on IV insulin).
- Transition from IV to SC insulin: give SC intermediate- or long-acting basal insulin 2–3 hours before stopping the IV infusion per DC 2018 (1–2 hours for rapid/short-acting insulin, or 1–2 hours for SC basal per Umpierrez 2024).
- Glucocorticoid-induced hyperglycaemia: monitor CBG for 48 hours after starting high-dose glucocorticoids (even without prior diabetes). Prednisone peaks in the afternoon/evening with relatively normal fasting BG — treat with basal-bolus + correction (morning NPH timed to prednisone is an alternative in ADA 2026, though trials vs basal-bolus are mixed). Taper insulin proactively as steroids step down to prevent hypoglycaemia.
- Enteral/parenteral nutrition: ~50% basal / 50% bolus matching feeds (shorter-acting NPH fits overnight cycled feeds); start IV dextrose immediately if tube feeds or TPN stop unexpectedly after insulin has been given.
- Ontario: Assistive Devices Program (ADP) funds insulin pumps and supplies for eligible T1DM patients; ODB covers CGM for eligible insulin-treated residents under provincial criteria.
Prepared 2026-11-19. Not yet verified — check every number against the sources.